Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis

Mycoses

Volumn 57, Issue 1, 2014, Pages 49-55

  Lewis, Russell E ^a,b   Georgiadou, Sarah P ^a   Sampsonas, Fotis ^a   Chamilos, George ^a   Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Lymphocytopenia; Mucormycosis; Risk index score

Indexed keywords

AMPHOTERICIN B; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; POSACONAZOLE;

ADOLESCENT; ADULT; APACHE; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKOCYTE TRANSFUSION; LUNG MYCOSIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTOPENIA; MUCORMYCOSIS; NEUTROPENIA; PREDICTIVE VALUE; PRIORITY JOURNAL; PULMONARY MUCORMYCOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; YOUNG ADULT;

LYMPHOCYTOPENIA; MUCORMYCOSIS; RISK INDEX SCORE;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; MUCORMYCOSIS; PROGNOSIS; RISK FACTORS; YOUNG ADULT;

EID: 84890798924     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12101     Document Type: Article

References (29)

1. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 2006; 20: 581-607.
2. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54(Suppl. 1): S23-34.
3. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556-69.
4. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood 2011; 118: 1216-24.
5. Kontoyiannis DP. Invasive mycoses: strategies for effective management. Am J Med 2012; 125(1 Suppl.): S25-38.
6. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61-e65.
7. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503-9.
8. Spellberg B, Kontoyiannis DP, Fredricks D et al. Risk factors for mortality in patients with mucormycosis. Med Mycol 2012; 50: 611-8.
9. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
10. Larone DH. Medically Important Fungi, 4th edn. Washington, DC: DCAP, 2002.
11. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
12. Lanternier F, Dannaoui E, Morizot G et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis 2012; 54(Suppl. 1): S35-43.
13. Hammond SP, Baden LR, Marty FM. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother 2011; 55: 5018-21.
14. Pagano L, Valentini CG, Posteraro B et al. Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). J Chemother 2009; 21: 322-9.
15. Cordonnier C, Ribaud P, Herbrecht R et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006; 42: 955-63.
16. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-40.
17. Ribaud P, Chastang C, Latge JP et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322-30.
18. Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827-33.
19. Baddley JW, Andes DR, Marr KA et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50: 1559-67.
20. Singh N, Avery RK, Munoz P et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36: 46-52.
21. Skiada A, Lanternier F, Groll AH et al. Diagnosis and treatment of mucormycosis in patients with haematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2013; 98:492-504.
22. Skiada A, Pagano L, Groll A et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 1859-67.
23. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30: 851-6.
24. Pagano L, Offidani M, Fianchi L et al. Mucormycosis in hematologic patients. Haematologica 2004; 89: 207-14.
25. Pagano L, Ricci P, Tonso A et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto). Br J Haematol 1997; 99: 331-6.
26. Schmidt S, Tramsen L, Perkhofer S et al. Characterization of the cellular immune responses to Rhizopus oryzae with potential impact on immunotherapeutic strategies in hematopoietic stem cell transplantation. J Infect Dis 2012; 206: 135-9.
27. Potenza L, Vallerini D, Barozzi P et al. Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. Blood 2011; 118: 5416-9.
28. Spellberg B, Ibrahim A, Roilides E et al. Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis 2012; 54(Suppl. 1): S73-S78.
29. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48: 1743-51.